HRP20200408T1 - Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa - Google Patents

Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa Download PDF

Info

Publication number
HRP20200408T1
HRP20200408T1 HRP20200408TT HRP20200408T HRP20200408T1 HR P20200408 T1 HRP20200408 T1 HR P20200408T1 HR P20200408T T HRP20200408T T HR P20200408TT HR P20200408 T HRP20200408 T HR P20200408T HR P20200408 T1 HRP20200408 T1 HR P20200408T1
Authority
HR
Croatia
Prior art keywords
compound
pharmaceutically acceptable
solvate
image
acceptable salt
Prior art date
Application number
HRP20200408TT
Other languages
English (en)
Inventor
Bart Rudolf Romanie Kesteleyn
Pierre Jean-Marie Bernard Raboisson
Jean-François BONFANTI
Tim Hugo Maria Jonckers
Dorothée Alice Marie-Eve Bardiot
Arnaud Didier M Marchand
Original Assignee
Janssen Pharmaceuticals, Inc.
Katholieke Universiteit Leuven, K.U. Leuven R&D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals, Inc., Katholieke Universiteit Leuven, K.U. Leuven R&D filed Critical Janssen Pharmaceuticals, Inc.
Publication of HRP20200408T1 publication Critical patent/HRP20200408T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Claims (8)

1. Spoj formule (I) [image] njegov stereoizomerni oblik, farmaceutski prihvatljiva sol, solvat ili polimorf koji sadrži mono- ili di-supstituiranu indolnu skupinu; navedeni spoj je odabran iz skupine pri čemu: R1 je H, R2 je F ili Cl i R3 je H ili CH3; R1 je F, R2 je F i R3 je H; R1 je CH3, R2 je OCH3 i R3 je H; R1 je CH3, R2 je F i R3 je H; R1 je CH3, R2 je H i R3 je F; R1 je Cl, R2 je H i R3 je CH3; R1 je OCF3, R2 je H ili OCH3 i R3 je H i R1 je OCF3R, R2 je H i R3 je CH3.
2. Spoj ili njegov stereoizomerni oblik, njegova farmaceutski prihvatljiva sol, solvat ili polimorf prema zahtjevu 1 naznačen time što je navedeni spoj odabran iz skupine koju čine: [image] [image] [image] [image]
3. Farmaceutski pripravak, naznačen time što sadrži spoj formule (I) ili njegov stereoizomerni oblik, njegovu farmaceutski prihvatljivu sol, solvat ili polimorf prema zahtjevu 1 ili 2 zajedno s jednom ili više farmaceutski prihvatljivih pomoćnih tvari, razrjeđivača ili nosača.
4. Spoj formule (I) ili njegov stereoizomerni oblik, farmaceutski prihvatljiva sol, solvat ili polimorf prema zahtjevu 1 ili farmaceutski pripravak prema zahtjevu 3 naznačen time što se koristi kao lijek.
5. Spoj formule (I) ili njegov stereoizomerni oblik, farmaceutski prihvatljiva sol, solvat ili polimorf prema zahtjevu 1 ili farmaceutski pripravak prema zahtjevu 3 naznačen time što je namijenjen upotrebi u liječenju denga virusa.
6. Spoj koji je predstavljen slijedećom strukturnom formulom (I) [image] njegov stereoizomerni oblik, farmaceutski prihvatljiva sol, solvat ili polimorf koji sadrže mono- ili di-supstituiranu indolnu skupinu; te je navedeni spoj je odabran iz skupine u kojoj: R1 je H, R2 je F ili Cl i R3 je H ili CH3; R1 je F, R2 je F i R3 je H; R1 je CH3, R2 je OCH3 i R3 je H; R1 je CH3, R2 je F i R3 je H; R1 je CH3, R2 je H i R3 je F; R1 je Cl, R2 je H i R3 je CH3; R1 je OCF3, R2 je H ili OCH3 i R3 je H i R1 je OCF3, R2 je H i R3 je CH3 naznačen time što je namijenjen upotrebi za inhibiranje replikacije denga virusa u biološkom uzorku ili pacijentu.
7. Spoj za uporabu prema zahtjevu 6 naznačen time što nadalje obuhvaća zajedničko davanje dodatnog terapijskog sredstva.
8. Spoj za uporabu prema zahtjevu 7 naznačen time što je navedeno dodatno terapeutsko sredstvo drugo antivirusno sredstvo.
HRP20200408TT 2015-09-16 2020-03-12 Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa HRP20200408T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15185522 2015-09-16
EP16163465 2016-04-01
EP16767235.1A EP3350163B1 (en) 2015-09-16 2016-09-15 Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
PCT/EP2016/071852 WO2017046258A1 (en) 2015-09-16 2016-09-15 Mono- or di-substituted indole derivatives as dengue viral replication inhibitors

Publications (1)

Publication Number Publication Date
HRP20200408T1 true HRP20200408T1 (hr) 2020-06-12

Family

ID=56958913

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200408TT HRP20200408T1 (hr) 2015-09-16 2020-03-12 Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa

Country Status (37)

Country Link
US (1) US10786484B2 (hr)
EP (1) EP3350163B1 (hr)
JP (2) JP7045984B2 (hr)
KR (1) KR20180051563A (hr)
CN (1) CN108368044B (hr)
AU (1) AU2016323535B2 (hr)
CA (1) CA2996856C (hr)
CL (1) CL2018000697A1 (hr)
CO (1) CO2018003369A2 (hr)
CR (1) CR20180214A (hr)
CY (1) CY1122792T1 (hr)
DK (1) DK3350163T3 (hr)
EA (1) EA035679B1 (hr)
EC (1) ECSP18020039A (hr)
ES (1) ES2778431T3 (hr)
HK (1) HK1258320A1 (hr)
HR (1) HRP20200408T1 (hr)
IL (1) IL258031B (hr)
JO (1) JO3633B1 (hr)
LT (1) LT3350163T (hr)
MA (1) MA42811B1 (hr)
MD (1) MD3350163T2 (hr)
ME (1) ME03674B (hr)
MX (1) MX2018003256A (hr)
MY (1) MY188347A (hr)
NI (1) NI201800040A (hr)
PE (1) PE20181007A1 (hr)
PH (1) PH12018500569A1 (hr)
PL (1) PL3350163T3 (hr)
PT (1) PT3350163T (hr)
RS (1) RS60039B1 (hr)
SI (1) SI3350163T1 (hr)
TW (1) TWI758256B (hr)
UA (1) UA123672C2 (hr)
UY (1) UY36904A (hr)
WO (1) WO2017046258A1 (hr)
ZA (1) ZA201801764B (hr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
KR101818521B1 (ko) * 2011-11-16 2018-01-16 대우조선해양 주식회사 마이크로채널 열교환기용 2상 유체 공급장치 및 그 방법
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PE20220507A1 (es) 2015-12-16 2022-04-07 Loxo Oncology Inc Compuestos utiles como inhibidores de cinasa
MX2018011784A (es) 2016-03-31 2019-02-13 Janssen Pharmaceuticals Inc Derivados de indol sustituidos como inhibidores de la replicacion virica del dengue.
WO2017167953A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
BR112018068956A2 (pt) 2016-04-01 2019-01-22 Janssen Pharmaceuticals Inc derivados do composto indol substituídos como inibidores da replicação viral da dengue
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) * 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PE20200342A1 (es) 2017-05-22 2020-02-14 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
ES2929667T3 (es) 2017-05-22 2022-11-30 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
WO2003050295A2 (en) 2001-12-12 2003-06-19 Conforma Therapeutics Corporation Assays and implements for determining and modulating hsp90 binding activity
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
JP2008526980A (ja) 2005-01-14 2008-07-24 ジェネラブズ テクノロジーズ インコーポレーティッド ウイルス感染症を治療するためのインドール誘導体
US20060194835A1 (en) 2005-02-09 2006-08-31 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
FR2928645A1 (fr) * 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
CA2726985A1 (en) 2008-06-03 2009-12-10 Siga Technologies, Inc. Small molecule inhibitors for the treatment or prevention of dengue virus infection
AU2009283195A1 (en) * 2008-08-18 2010-02-25 Yale University MIF modulators
US8143259B2 (en) 2008-08-19 2012-03-27 Janssen Pharmaceutica, Nv Cold menthol receptor antagonists
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
GB0910003D0 (en) * 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
PT2523951E (pt) 2010-01-15 2015-09-14 Gilead Sciences Inc Inibidores de vírus flaviviridae
JP5716205B2 (ja) * 2011-03-29 2015-05-13 学校法人日本大学 グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) * 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
MX368158B (es) * 2013-10-23 2019-09-20 Janssen Sciences Ireland Uc Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
JP6464176B2 (ja) 2014-01-31 2019-02-06 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 芳香族p2’基を有する第xia因子阻害剤としてのマクロ環
ME03344B (me) 2014-10-01 2019-10-20 Janssen Pharmaceuticals Inc Mono- ili di-supstituisani indoli kao inнibitori replikacije denga virusa
SG11201702463YA (en) 2014-10-01 2017-04-27 Janssen Pharmaceuticals Inc Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
NO2721243T3 (hr) 2014-10-01 2018-10-20
JOP20150335B1 (ar) * 2015-01-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EP3370698B1 (en) 2015-11-03 2022-01-26 Zoetis Services LLC Sol-gel polymer composites and uses thereof
BR112018068538B1 (pt) 2016-03-31 2023-12-12 Takeda Pharmaceutical Company Limited Composto, medicamento, e, uso de um composto
WO2017167953A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
MX2018011784A (es) 2016-03-31 2019-02-13 Janssen Pharmaceuticals Inc Derivados de indol sustituidos como inhibidores de la replicacion virica del dengue.
UA123912C2 (uk) 2016-04-01 2021-06-23 Басф Се Біциклічні сполуки
BR112018068956A2 (pt) 2016-04-01 2019-01-22 Janssen Pharmaceuticals Inc derivados do composto indol substituídos como inibidores da replicação viral da dengue
IL296966A (en) 2016-04-01 2022-12-01 Amgen Inc Chimeric flt-3 receptors and methods of using them
CN113150170A (zh) 2016-04-01 2021-07-23 凯德药业股份有限公司 嵌合受体及其方法和用途
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EA039392B1 (ru) 2016-04-01 2022-01-21 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Способ лечения рака с применением замещенного аминопуринового соединения
TW202313671A (zh) 2016-04-01 2023-04-01 美商凱特製藥公司 嵌合抗原和t細胞受體及使用方法
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PE20200342A1 (es) 2017-05-22 2020-02-14 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
ES2929667T3 (es) 2017-05-22 2022-11-30 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue

Also Published As

Publication number Publication date
MA42811A (fr) 2018-07-25
AU2016323535A1 (en) 2018-03-08
RS60039B1 (sr) 2020-04-30
CO2018003369A2 (es) 2018-07-10
JO3633B1 (ar) 2020-08-27
CR20180214A (es) 2018-05-14
CN108368044B (zh) 2021-06-15
MY188347A (en) 2021-12-02
CN108368044A (zh) 2018-08-03
ZA201801764B (en) 2021-04-28
EP3350163B1 (en) 2019-12-25
PH12018500569A1 (en) 2018-09-17
EA201890723A1 (ru) 2018-08-31
JP2018528222A (ja) 2018-09-27
TWI758256B (zh) 2022-03-21
DK3350163T3 (da) 2020-03-16
WO2017046258A1 (en) 2017-03-23
PT3350163T (pt) 2020-03-23
LT3350163T (lt) 2020-04-10
CY1122792T1 (el) 2021-05-05
NI201800040A (es) 2018-07-24
US10786484B2 (en) 2020-09-29
IL258031B (en) 2021-03-25
HK1258320A1 (zh) 2019-11-08
CL2018000697A1 (es) 2018-07-06
ECSP18020039A (es) 2018-04-30
KR20180051563A (ko) 2018-05-16
EA035679B1 (ru) 2020-07-24
EP3350163A1 (en) 2018-07-25
MX2018003256A (es) 2018-11-09
US20180256544A1 (en) 2018-09-13
PL3350163T3 (pl) 2020-08-24
PE20181007A1 (es) 2018-06-26
MA42811B1 (fr) 2020-03-31
ME03674B (me) 2020-10-20
ES2778431T3 (es) 2020-08-10
UY36904A (es) 2017-03-31
UA123672C2 (uk) 2021-05-12
JP7045984B2 (ja) 2022-04-01
AU2016323535B2 (en) 2021-02-18
IL258031A (en) 2018-05-31
SI3350163T1 (sl) 2020-07-31
CA2996856C (en) 2023-08-01
TW201722912A (zh) 2017-07-01
MD3350163T2 (ro) 2020-06-30
JP2021193092A (ja) 2021-12-23
CA2996856A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
HRP20200408T1 (hr) Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa
HRP20210847T1 (hr) Supstituirani derivati indola kao inhibitori replikacije denga virusa
HRP20211278T1 (hr) Supstituirani derivati indolina kao inhibitori replikacije denga virusa
HRP20210942T1 (hr) Supstituirani derivati indolina kao inhibitori replikacije denga virusa
HRP20211223T1 (hr) Heterociklički indoli za upotrebu kod infekcije virusom influence
HRP20210038T1 (hr) Pirolopirimidini za uporabu u infekciji virusom gripe
HRP20211224T1 (hr) Derivati pirimidina za liječenje virusnih infekcija
HRP20202051T1 (hr) Aril supstituirani pirimidini za uporabu kod infekcije virusom influence
HRP20211102T1 (hr) Supstituirani derivati indolina kao inhibitori replikacije denga virusa
JP2019509276A5 (hr)
EA201891876A1 (ru) Тетрациклические пиридоновые соединения в качестве противовирусных средств
ZA202006378B (en) N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof
JP2017531619A5 (hr)
JP2019510034A5 (hr)
HRP20201023T1 (hr) Dioksilan analozi uridina za liječenje raka
HRP20211782T1 (hr) Derivati indola kao inhibitori replikacije denga virusa
HRP20210724T1 (hr) Supstituirani derivati indolina kao inhibitori replikacije denga virusa
AR111878A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
HRP20161379T1 (hr) Inhibitori hepatitis c virusa
HRP20161125T1 (hr) Makrociklički purini za liječenje virusnih infekcija
JP2019510027A5 (hr)
EA202090486A3 (ru) Соединения для лечения спинальной мышечной атрофии
EA201590450A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
EA201791019A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
BR112012000287B8 (pt) composição farmacêutica para um inibidor de protease viral de hepatite c